EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal KRAS ctDNA Monitoring and Radiological Assessment in Patients with Advanced Colorectal Cancer Receiving D-Isoascorbic Acid (D-VC) in Combination with Arsenic Trioxide (ATO): A Pilot Study

Akbota Aitkulova, Nuray Tynyshtykbayeva, Diana Samatkyzy, Tomiris Shakhmarova, Ainur Akilzhanova, Dos Sarbassov

Current Oncology · 15.11.2026 · 33 (11) · 708

DOI: 10.3390/curroncol33110708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 15.11.2026. Verfasst von Akbota Aitkulova und 5 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumour DNA (ctDNA) kinetics are increasingly used to assess treatment response in metastatic colorectal cancer (mCRC). However, data on longitudinal ctDNA changes during experimental metabolic or pro-oxidant therapies are limited. This pilot study evaluated longitudinal KRAS ctDNA measurements and their relationship with radiological changes in patients with advanced colorectal cancer treated with arsenic trioxide (ATO) and D-isomer vitamin C (D-VC).

Methods

Five patients with advanced, heavily pretreated colorectal cancer (CRC) underwent serial contrast-enhanced computed tomography (CT) and blood sampling as part of the phase I/II BR11765589 clinical trial. Tumour genomic profiling was performed using the TruSight Oncology 500 assay on archived formalin-fixed paraffin-embedded (FFPE) tissue or baseline plasma cell-free DNA. KRAS codon 12 variants were monitored at multiple time points using a multiplex digital PCR (dPCR) assay. Longitudinal ctDNA measurements were compared with changes in target lesion size according to RECIST 1.1.

Results

Somatic alterations involving genes in colorectal cancer-associated pathways were identified across the cohort. In Patient 128, KRAS p.G12D was detected in archived tumour tissue, whereas KRAS p.G12V was detected in the later plasma sample. Across seven paired longitudinal observations from five patients, the percentage change in target lesion diameter was inversely correlated with the log2 fold-change in KRAS-mutant ctDNA copies (Spearman ρ = −0.71, p = 0.088). In Patient 120, plasma KRAS p.G12V copies decreased from 97.40 copies/µL at baseline to 30.07 copies/µL at month 5, whereas target lesion diameter increased from 4.20 to 6.06 cm. In Patient 130, mutant ctDNA copies increased by 79.6%, while target lesion diameter decreased by 10.3%.

Conclusions

Longitudinal KRAS-mutant ctDNA measurements and radiological assessments showed discordant changes in this small cohort of heavily pretreated patients receiving ATO/D-VC. The difference between the KRAS variants detected in archived tissue and later plasma in Patient 128, together with the discordant longitudinal measurements, indicates that tissue, plasma and radiological assessments may provide different information at different stages of treatment. Further studies in larger cohorts with standardized sampling and imaging schedules are required to evaluate the clinical relevance of longitudinal KRAS-mutant ctDNA during ATO/D-VC treatment.

Förderung

  • Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan

Zitieren

APA

Aitkulova, A., Tynyshtykbayeva, N., Samatkyzy, D., Shakhmarova, T., Akilzhanova, A., & Sarbassov, D. (2026). Longitudinal KRAS ctDNA Monitoring and Radiological Assessment in Patients with Advanced Colorectal Cancer Receiving D-Isoascorbic Acid (D-VC) in Combination with Arsenic Trioxide (ATO): A Pilot Study. Current Oncology, 33(11), 708. https://doi.org/10.3390/curroncol33110708

Vancouver

Aitkulova A, Tynyshtykbayeva N, Samatkyzy D, Shakhmarova T, Akilzhanova A, Sarbassov D. Longitudinal KRAS ctDNA Monitoring and Radiological Assessment in Patients with Advanced Colorectal Cancer Receiving D-Isoascorbic Acid (D-VC) in Combination with Arsenic Trioxide (ATO): A Pilot Study. Current Oncology. 2026;33(11):708. doi:10.3390/curroncol33110708

BibTeX
@article{Aitkulova2026,
  author = {Aitkulova, Akbota and Tynyshtykbayeva, Nuray and Samatkyzy, Diana and Shakhmarova, Tomiris and Akilzhanova, Ainur and Sarbassov, Dos},
  title = {Longitudinal KRAS ctDNA Monitoring and Radiological Assessment in Patients with Advanced Colorectal Cancer Receiving D-Isoascorbic Acid (D-VC) in Combination with Arsenic Trioxide (ATO): A Pilot Study},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {11},
  pages = {708},
  doi = {10.3390/curroncol33110708}
}
Kostenlos starten →